Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beijing Attracts Billion-Yuan Investment For Health Care Projects

This article was originally published in PharmAsia News

Executive Summary

To accelerate the development of the biopharmaceutical industry, Beijing Municipal Bureau of Industrial Development is stepping up efforts to provide investors with policy consulting and tracking services. The city has this year signed up eight major health care investments totaling 3.83 billion yuan ($548 million). The projects comprise: (1) joint production of MMR (measles, mumps and rubella) vaccines by GSK and Xili Pharmaceutical Group; (2) Genzyme Biotech Beijing's R&D and laboratory production project; (3) Kaizheng Biotech's human blood substitutes and new drug R&D production base; (4) Xiuzheng Pharmaceutical Group's industrial park; (5) Korean Daewoong Pharmaceutical's R&D center and production base; (6) Tiandao Biotech's monoclonal antibody R&D and production base; (7) Mindray's Beijing academic institution; and (8) Genova Biotech's Novaferon production base. (Click here for more - Chinese language)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC068422

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel